CA-GLOBALLOGIC
8.4.2024 14:38:30 CEST | Business Wire | Press release
GlobalLogic, a Hitachi group company, today announced a first-of-its-kind Platform-of-Platforms architecture designed to support deployment of enterprise-grade artificial intelligence (AI). GlobalLogic has designed the architecture to address the critical challenges every enterprise must overcome when operationalizing AI and generative AI (GenAI) at scale.
To realize the potential that AI promises, enterprises must address data privacy and security requirements, prevent intellectual property (IP) leakage and manage legal risks. They also need to identify an approach that allows for technical agility as new models, platforms and other innovations take shape. At the same time, leaders must manage organizational change and find effective strategies for controlling costs and driving return on AI/GenAI investments.
With over a decade of experience in delivering and deploying AI in software products and enterprise platforms, GlobalLogic offers a unique perspective on the design, data and engineering challenges of enterprise-grade, production-ready AI and GenAI. Created in partnership with leading hyperscalers and leveraging their foundational GenAI capabilities, GlobalLogic’s architecture is the first of its kind for unifying and industrializing enterprise-grade AI and GenAI solutions.
GlobalLogic identifies responsibility, reliability and reusability as key to enterprise-grade AI
“As companies work to move from AI and GenAI prototypes to enterprise-scale deployments, it has become clear that using this technology requires far more than sending prompts to a large language model (LLM),” said Sumit Sood, COO and Head of Engineering, GlobalLogic. “We have been helping enterprises adopt GenAI since 2021 and ‘traditional’ AI for much longer, often in life-critical situations. We understand what needs to be done to ensure responsibility, reliability and reusability in AI platforms.”
Sood explains that the responsibility tenet focuses on the goal of offering responses that are accurate, lawful and in compliance with security and governance requirements. The reliability tenet requires mechanisms for correcting model drift, hallucinations and security threats over time. Finally, the reusability tenet is crucial to implementing common data ingestion, preparation and model training and shared consumption mechanisms – which help contain costs and mitigate risk by preventing duplicative work.
GlobalLogic’s AI Platform-of-Platforms architecture addresses critical needs related to observability, security, governance and consumption. It makes it possible to integrate best-of-breed models, algorithms and solutions whether deployed in the cloud or on premises. It also includes accelerators for rapidly deploying some of the most sought-after use cases, including customer support and operations, software development and legacy migration, and enterprise knowledge management.
“The GenAI landscape is highly dynamic,” Sood said. “In an environment where the ‘best’ technology can change month to month or even week to week, GlobalLogic’s Platform-of-Platforms approach lets our clients pick the winners to deliver the best enterprise-class GenAI to support their business outcomes.”
To learn more about GlobalLogic’s AI solutions and advisory capabilities, visit www.globallogic.com/services/offerings/generative-ai/.
ABOUT GLOBALLOGIC
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408417447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
